Aug 11, 2025 4:01 pm EDT Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
Jul 24, 2025 8:00 am EDT Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-celĀ®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease